These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1052 related items for PubMed ID: 21597022

  • 21. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
    Öhrling K, Karlberg M, Edler D, Hallström M, Ragnhammar P.
    Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
    Li P, Fang YJ, Li F, Ou QJ, Chen G, Ma G.
    Br J Cancer; 2013 Apr 02; 108(6):1238-44. PubMed ID: 23481186
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.
    Kim JE, Hong YS, Ryu MH, Lee JL, Chang HM, Lim SB, Kim JH, Jang SJ, Kim MJ, Yu CS, Kang YK, Kim JC, Kim TW.
    Cancer Sci; 2011 Sep 02; 102(9):1706-11. PubMed ID: 21679278
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A, Fléjou JF, Emile JF, Des GG, Cuilliere-Dartigues P, Malka D, Lecaille C, Validire P, Louvet C, Rougier P, de Gramont A, Bonnetain F, Praz F, Taïeb J.
    Clin Cancer Res; 2011 Dec 01; 17(23):7470-8. PubMed ID: 21998335
    [Abstract] [Full Text] [Related]

  • 29. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
    Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M.
    J Clin Oncol; 2009 Apr 10; 27(11):1814-21. PubMed ID: 19273709
    [Abstract] [Full Text] [Related]

  • 30. Microsatellite instability testing and its role in the management of colorectal cancer.
    Kawakami H, Zaanan A, Sinicrope FA.
    Curr Treat Options Oncol; 2015 Jul 10; 16(7):30. PubMed ID: 26031544
    [Abstract] [Full Text] [Related]

  • 31. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.
    French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN.
    Clin Cancer Res; 2008 Jun 01; 14(11):3408-15. PubMed ID: 18519771
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.
    Li W, Zhi W, Zou S, Qiu T, Ling Y, Shan L, Shi S, Ying J.
    PLoS One; 2015 Jun 01; 10(6):e0128202. PubMed ID: 26042813
    [Abstract] [Full Text] [Related]

  • 35. Association of family history with cancer recurrence and survival among patients with stage III colon cancer.
    Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS.
    JAMA; 2008 Jun 04; 299(21):2515-23. PubMed ID: 18523220
    [Abstract] [Full Text] [Related]

  • 36. Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer.
    Rasola C, Laurent-Puig P, André T, Falcoz A, Lepage C, Aparicio T, Bouché O, Lievre A, Mineur L, Bennouna J, Louvet C, Bachet JB, Borg C, Vernerey D, Lonardi S, Taieb J.
    Eur J Cancer; 2023 Nov 04; 194():113321. PubMed ID: 37797388
    [Abstract] [Full Text] [Related]

  • 37. Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
    Bendardaf R, Lamlum H, Ristamäki R, Korkeila E, Syrjänen K, Pyrhönen S.
    Acta Oncol; 2008 Nov 04; 47(6):1046-53. PubMed ID: 17943475
    [Abstract] [Full Text] [Related]

  • 38. Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair-Deficient Colon Cancers: Implications for Prognosis.
    Yoon HH, Shi Q, Heying EN, Muranyi A, Bredno J, Ough F, Djalilvand A, Clements J, Bowermaster R, Liu WW, Barnes M, Alberts SR, Shanmugam K, Sinicrope FA.
    Clin Cancer Res; 2019 Jan 01; 25(1):125-133. PubMed ID: 30301825
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
    Zhu J, Ke G, Bi R, Wu X.
    J Surg Oncol; 2020 Sep 01; 122(3):538-546. PubMed ID: 32396667
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 53.